An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

229

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

February 19, 2025

Study Completion Date

February 19, 2025

Conditions
Advanced Cancer
Interventions
BIOLOGICAL

Relatlimab

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

DRUG

BMS-986205

Specified dose on specified days

BIOLOGICAL

Ipilimumab

Specified dose on specified days

Trial Locations (22)

1011

Local Institution - 0008, Lausanne

2065

Local Institution - 0012, Wollstonecraft

6009

Local Institution - 0011, Nedlands

8091

Local Institution - 0007, Zurich

13385

Local Institution - 0017, Marseille

21231

Local Institution - 0004, Baltimore

28041

Local Institution - 0021, Madrid

28050

Local Institution - 0018, Madrid

29011

Local Institution - 0022, Málaga

31008

Local Institution - 0020, Pamplona

31059

Local Institution - 0016, Toulouse

38138

Local Institution - 0001, Germantown

47014

Local Institution - 0010, Forlì

63110

Local Institution - 0005, St Louis

80045

Local Institution - 0003, Aurora

80131

Local Institution - 0009, Napoli

91010

Local Institution - 0006, Duarte

94800

Local Institution - 0015, Villejuif

00144

Local Institution - 0023, Rome

08036

Local Institution - 0019, Barcelona

OX3 7LE

Local Institution - 0013, Headington

NE7 7DN

Local Institution - 0014, Newcastle upon Tyne

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY